| Literature DB >> 29170471 |
Roberto Salgado1,2,3, Helen Moore4, John W M Martens5, Tracy Lively4, Shakun Malik4, Ultan McDermott6, Stefan Michiels7, Jeffrey A Moscow4, Sabine Tejpar8, Tawnya McKee4, Denis Lacombe9.
Abstract
The availability of targeted anticancer drugs and the relative affordability of genomic analyses has led to a growing expectation among patients with cancer that they can receive personalized treatment based on the genomic signature of their tumour. Here, we discuss some of the challenges and steps needed to bring such approaches into routine practice.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29170471 DOI： 10.1038/nrd.2017.218
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694